Market Closed -
Canadian Securities Exchange
03:59:59 2024-07-08 pm EDT
|
5-day change
|
1st Jan Change
|
2.13
CAD
|
-0.47%
|
|
-0.47%
|
+18.99%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
940.1
|
2,343
|
1,929
|
545.3
|
459.7
|
549.3
|
-
|
-
|
Enterprise Value (EV)
1 |
891
|
2,391
|
2,191
|
1,094
|
1,034
|
1,035
|
1,008
|
549.3
|
P/E ratio
|
-18.6
x
|
-25.3
x
|
-5.44
x
|
-2.54
x
|
-2.5
x
|
-36.5
x
|
184
x
|
8.22
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
7.31
x
|
4.92
x
|
2.35
x
|
0.65
x
|
0.6
x
|
0.74
x
|
0.69
x
|
0.63
x
|
EV / Revenue
|
6.93
x
|
5.02
x
|
2.67
x
|
1.3
x
|
1.34
x
|
1.39
x
|
1.27
x
|
0.63
x
|
EV / EBITDA
|
112
x
|
20.6
x
|
11.3
x
|
6.3
x
|
5.95
x
|
5.07
x
|
4.65
x
|
2.28
x
|
EV / FCF
|
-7.62
x
|
-26.8
x
|
-27.6
x
|
-17
x
|
325
x
|
26.6
x
|
24
x
|
-
|
FCF Yield
|
-13.1%
|
-3.73%
|
-3.62%
|
-5.88%
|
0.31%
|
3.76%
|
4.17%
|
-
|
Price to Book
|
-
|
-
|
-
|
0.92
x
|
1.02
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
136,840
|
237,757
|
290,734
|
301,783
|
340,470
|
351,616
|
-
|
-
|
Reference price
2 |
6.870
|
9.853
|
6.636
|
1.807
|
1.350
|
1.562
|
1.562
|
1.562
|
Announcement Date
|
4/27/20
|
3/25/21
|
3/23/22
|
3/16/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
128.5
|
476.3
|
821.7
|
842.7
|
770.9
|
745.3
|
793.1
|
867.8
|
EBITDA
1 |
7.989
|
116
|
194
|
173.6
|
173.6
|
204.2
|
216.7
|
241.4
|
EBIT
1 |
-34.26
|
55.84
|
-217.4
|
-83.39
|
-87.82
|
118.2
|
138.4
|
196.7
|
Operating Margin
|
-26.65%
|
11.73%
|
-26.45%
|
-9.9%
|
-11.39%
|
15.86%
|
17.44%
|
22.67%
|
Earnings before Tax (EBT)
1 |
-50.84
|
7.158
|
-256.7
|
-126
|
-146.9
|
66.23
|
91.48
|
172.6
|
Net income
1 |
-43.2
|
-81.92
|
-296.8
|
-215.1
|
-175.5
|
-20.53
|
3.461
|
125.6
|
Net margin
|
-33.61%
|
-17.2%
|
-36.13%
|
-25.53%
|
-22.77%
|
-2.75%
|
0.44%
|
14.47%
|
EPS
2 |
-0.3700
|
-0.3900
|
-1.220
|
-0.7100
|
-0.5400
|
-0.0428
|
0.008500
|
0.1900
|
Free Cash Flow
1 |
-116.9
|
-89.1
|
-79.39
|
-64.28
|
3.179
|
38.94
|
42
|
-
|
FCF margin
|
-90.92%
|
-18.71%
|
-9.66%
|
-7.63%
|
0.41%
|
5.22%
|
5.3%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
1.83%
|
19.07%
|
19.38%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
1,213.6%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/27/20
|
3/25/21
|
3/23/22
|
3/16/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
217.8
|
214.4
|
218.2
|
210.5
|
199.6
|
194.2
|
197.9
|
190.6
|
188.2
|
184.3
|
184.6
|
185.5
|
190.7
|
191.7
|
194.5
|
EBITDA
1 |
56.99
|
50.75
|
50.59
|
41.74
|
30.53
|
29.28
|
40.48
|
49.05
|
54.83
|
53.16
|
49.95
|
50.39
|
52.06
|
50.46
|
51.94
|
EBIT
1 |
15.56
|
20.27
|
22.68
|
16.24
|
-142.6
|
3.586
|
-10.75
|
-107.8
|
27.1
|
29.16
|
30.69
|
30.85
|
32.28
|
30.95
|
31.66
|
Operating Margin
|
7.14%
|
9.45%
|
10.39%
|
7.72%
|
-71.44%
|
1.85%
|
-5.43%
|
-56.55%
|
14.4%
|
15.82%
|
16.62%
|
16.63%
|
16.92%
|
16.15%
|
16.28%
|
Earnings before Tax (EBT)
1 |
11.62
|
-0.868
|
15.34
|
15.48
|
-156
|
-11
|
-29.53
|
-119.2
|
12.82
|
15.95
|
16.23
|
16.37
|
17.68
|
16.73
|
17.44
|
Net income
1 |
-11.91
|
-23.68
|
-8.296
|
-3.249
|
-179.9
|
-27.81
|
-43.46
|
-113.4
|
2.635
|
-2.055
|
-6.475
|
-6.739
|
-5.403
|
-5.893
|
-5.389
|
Net margin
|
-5.47%
|
-11.04%
|
-3.8%
|
-1.54%
|
-90.13%
|
-14.32%
|
-21.96%
|
-59.53%
|
1.4%
|
-1.12%
|
-3.51%
|
-3.63%
|
-2.83%
|
-3.07%
|
-2.77%
|
EPS
2 |
-0.0300
|
-0.0900
|
-0.0500
|
-0.0300
|
-0.5400
|
-0.0913
|
-0.1200
|
-0.3400
|
0.0200
|
-0.0200
|
-0.0162
|
-0.0162
|
-0.0145
|
-0.0150
|
-0.0100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/23/22
|
5/18/22
|
8/17/22
|
11/15/22
|
3/16/23
|
5/24/23
|
8/16/23
|
11/15/23
|
3/13/24
|
5/15/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
48.2
|
261
|
549
|
574
|
486
|
458
|
-
|
Net Cash position
1 |
49.1
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
0.4153
x
|
1.348
x
|
3.16
x
|
3.307
x
|
2.379
x
|
2.114
x
|
-
|
Free Cash Flow
1 |
-117
|
-89.1
|
-79.4
|
-64.3
|
3.18
|
38.9
|
42
|
-
|
ROE (net income / shareholders' equity)
|
-7.48%
|
-13.8%
|
2.23%
|
-6.99%
|
-35.4%
|
-5%
|
-2.2%
|
-
|
ROA (Net income/ Total Assets)
|
-11.5%
|
-5.39%
|
0.91%
|
-2.88%
|
-12.2%
|
-1.5%
|
-0.7%
|
-
|
Assets
1 |
374.1
|
1,519
|
-32,626
|
7,467
|
1,436
|
1,369
|
-494.4
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
1.970
|
1.320
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-0.2100
|
-0.0500
|
-
|
-
|
0.1800
|
0.2800
|
0.2800
|
-
|
Capex
1 |
91.7
|
78.3
|
93.9
|
83
|
55.4
|
57.8
|
49.7
|
-
|
Capex / Sales
|
71.32%
|
16.44%
|
11.42%
|
9.85%
|
7.18%
|
7.76%
|
6.26%
|
-
|
Announcement Date
|
4/27/20
|
3/25/21
|
3/23/22
|
3/16/23
|
3/13/24
|
-
|
-
|
-
|
Last Close Price
1.562
USD Average target price
4.652
USD Spread / Average Target +197.76% Consensus |
1st Jan change
|
Capi.
|
---|
| +18.99% | 552M | | +57.48% | 823B | | -7.18% | 353B | | +15.37% | 320B | | +7.45% | 295B | | +13.62% | 239B | | +14.55% | 220B | | -0.33% | 219B | | +8.14% | 167B | | -2.99% | 159B |
Other Pharmaceuticals
|